NeuroBo Pharmaceuticals (NRBO) shares were up nearly 8% in recent trading Wednesday after the company reported its Q2 results.
The company reported Q2 net loss of $1.85 per diluted share, widening from a loss of $0.15 a year earlier.
Three analysts surveyed by Capital IQ expected a loss of $1.12
The company did not report revenue for the quarter ended June 30.
NeuroBo Pharmaceuticals said it had $27.9 million in cash as of June 30 and expects its cash position to fund the company's operations into Q2 2025.
Price: 4.01, Change: +0.29, Percent Change: +7.80
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.